1. Homepage
  2. Equities
  3. Denmark
  4. Nasdaq Copenhagen
  5. ViroGates A/S
  6. News
  7. Summary
    VIRO   DK0061030574

VIROGATES A/S

(VIRO)
Delayed Nasdaq Copenhagen  -  05/20 03:54:34 am EDT
77.00 DKK   +4.05%
05/10VIROGATES : Healthy growth
AQ
05/04VIROGATES ANNOUNCES ITS INTERIM REPORT FOR Q1, 2022 : Record quarterly revenue and doubling of clinical customers
AQ
05/04ViroGates A/S Reports Earnings Results for the First Quarter Ended March 31, 2022
CI
SummaryQuotesChartsNewsCalendarCompanyFinancials 
SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector news

ViroGates on positive EMA opinion regarding suPAR-guided anakinra treatment (Video)

12/17/2021 | 07:18am EDT

ViroGates published a press release yesterday announcing that the Committee for Medicinal Products for Human Use (CHMP), advisory board to the European Medicines Agency (EMA), has adopted a positive opinion of Kineret (anakinra) for suPAR-guided treatment of adult patients with COVID-19 pneumonia.

The full press release can be found here. CEO Jakob Knudsen was interviewed today by Alf Riple, Chief Analyst at Västra Hamnen Corporate Finance, about the significance of this announcement and its impact on ViroGates going forward.

The video clip is available here.

This video was created as a part of Market Focus, Västra Hamnen Corporate Finance’ commissioned research offering.

© Modular Finance, source Nordic Press Releases

All news about VIROGATES A/S
05/10VIROGATES : Healthy growth
AQ
05/04VIROGATES ANNOUNCES ITS INTERIM REPO : Record quarterly revenue and doubling of clinical c..
AQ
05/04ViroGates A/S Reports Earnings Results for the First Quarter Ended March 31, 2022
CI
05/03Invitation to ViroGates' Q1 2022 presentation
AQ
04/28Resolutions from the Annual General Meeting of ViroGates A/S
AQ
04/28ViroGates A/S Announces Board Changes
CI
04/19VIROGATES A/S : High blood sugar and suPAR levels independently worsen COVID-19 outcomes
PU
04/18ViroGates announces a current total of 33 clinical routine hospital customers and adjus..
AQ
04/13ViroGates gives notice to convene the Annual General Meeting on 28 April 2022
AQ
04/06ViroGates announces clinical routine use in Portugal
AQ
More news
Financials
Sales
Net income
Net Debt
P/E ratio
Yield
Capitalization 244 M 34,6 M 34,6 M
EV / Sales -1
EV / Sales 0
Nbr of Employees 14
Free-Float 47,5%
Chart VIROGATES A/S
Duration : Period :
ViroGates A/S Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends VIROGATES A/S
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Managers and Directors
Jakob Knudsen Chief Executive Officer
Mark Christian Hvidberg da Silva Chief Financial Officer
Lars Kongsbak Chairman
Jesper Eugen-Olsen Chief Scientific Officer
J÷rgen Axel Thorball Independent Director
Sector and Competitors
1st jan.Capi. (M$)
VIROGATES A/S-46.53%35
EXACT SCIENCES CORPORATION-31.68%9 355
BGI GENOMICS CO., LTD.-24.52%4 059
GUARDANT HEALTH, INC.-65.26%3 748
IOVANCE BIOTHERAPEUTICS, INC.-19.17%2 425
SEEGENE, INC.-30.57%1 715